Gene mutation in hereditary progressive dystonia with marked diurnal fluctuation (HPD), strictly defined dopa-responsive dystonia

Brain Dev. 2000 Sep:22 Suppl 1:S102-6. doi: 10.1016/s0387-7604(00)00152-2.

Abstract

Mutations of the guanosine triphosphate (GTP)-cyclohydrolase I (GCH-I) gene, which catalyzes the first step in the tetrahydrobiopterin (the natural cofactor for tyrosine hydroxylase) biosynthesis, are demonstrated to cause HPD, i.e. strictly defined dopa-responsive dystonia. We analyzed the GCH-I gene of patients who fulfilled clinical criteria for typical hereditary progressive dystonia (HPD) to finalize the diagnosis. Two novel point mutations in two independent families and one novel de novo point mutation in one sporadic patient were identified. In a Japanese family, a T-to-C transition was found at exon 2, which resulted in a substitution of Cys 141 to Arg. In another Japanese family, a C-to-T mutation in exon 4 caused a nonsense codon Gln180Stop. In a clinically sporadic Japanese patient, T-to-G transition in exon 1 brought Met 102 Arg missense mutation, which was not observed in its biological parents. These three mutations were not observed in previously reported 57 pedigrees/patients and no polymorphisms in the coding region of the GCH-I gene were identified. None of the mutations of GCH-I gene in HPD reported to date or in this study have been detected more than once in any ethnicity suggesting a relatively high spontaneous mutation rate in this gene.

MeSH terms

  • DNA Mutational Analysis
  • Dihydroxyphenylalanine / therapeutic use
  • Dystonia / drug therapy
  • Dystonia / genetics*
  • Dystonia / metabolism
  • Dystonic Disorders / drug therapy
  • Dystonic Disorders / genetics*
  • Dystonic Disorders / metabolism
  • Exons
  • Female
  • GTP Cyclohydrolase / genetics*
  • Humans
  • Male
  • Pedigree

Substances

  • Dihydroxyphenylalanine
  • GTP Cyclohydrolase